GSK3B and ovarian carcinoma: In this relatively small clinical cohort, we found that levels of GSK3β transcripts were significantly higher in patients with ovarian cancer–associated recurrence (p < 0.05 vs. incidence free) and in patients who died of ovarian cancer (p < 0.05 vs. patients who are alive) (Figure 5B,C, respectively).